These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20937523)

  • 1. Purification, characterization and in vivo studies of salmon heparin.
    Flengsrud R; Larsen ML; Ødegaard OR
    Thromb Res; 2010 Dec; 126(6):e409-17. PubMed ID: 20937523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparin is responsible for the anti-Xa activity of Desmin 370.
    Brieger D; Dawes J
    Thromb Haemost; 1996 Feb; 75(2):286-91. PubMed ID: 8815578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
    Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effects.
    Saivin S; Petitou M; Lormeau JC; Dupouy D; Sié P; Caranobe C; Houin G; Boneu B
    Thromb Haemost; 1992 Mar; 67(3):346-51. PubMed ID: 1322569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Terminal Sequence and Main Characteristics of Atlantic Salmon (Salmo salar) Albumin.
    Xu Y; Ding Z
    Prep Biochem Biotechnol; 2005; 35(4):283-90. PubMed ID: 16239193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
    Brophy DF; Martin EJ; Best AM; Gehr TW; Carr ME
    J Thromb Haemost; 2004 Aug; 2(8):1299-304. PubMed ID: 15304034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations of the chronometric assays to determine plasma antifactor Xa activity during low molecular weight heparin therapy.
    Boneu B; Faruel-Bille V; Pierrejean D; Gabaig AM
    Nouv Rev Fr Hematol (1978); 1991; 33(4):287-91. PubMed ID: 1664095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.
    Briant L; Caranobe C; Saivin S; Sié P; Bayrou B; Houin G; Boneu B
    Thromb Haemost; 1989 Jun; 61(3):348-53. PubMed ID: 2552603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and characterization of a heparin with high anticoagulant activity from the clam Tapes phylippinarum: evidence for the presence of a high content of antithrombin III binding site.
    Cesaretti M; Luppi E; Maccari F; Volpi N
    Glycobiology; 2004 Dec; 14(12):1275-84. PubMed ID: 15253929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mode of action of CY216 and CY222 in plasma.
    Béguin S; Wielders S; Lormeau JC; Hemker HC
    Thromb Haemost; 1992 Jan; 67(1):33-41. PubMed ID: 1319616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions.
    Barrowcliffe TW; Le Shirley Y
    Thromb Haemost; 1989 Nov; 62(3):950-4. PubMed ID: 2556814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
    Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R
    Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparative study of the action of preparations of high- and low-molecular weight heparin on hemostatic indices in vitro and in their intravenous administration to animals].
    Kudriashov BA; Pastorova VE; Liapina LA; Kondashevskaia MV; Azieva LD; Sukhanov IuS; Fedeniuk PV; Vasiukov SE; Cherstvova LG
    Eksp Klin Farmakol; 1992; 55(1):35-8. PubMed ID: 1339042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disaccharide analysis of chondroitin and heparin from farmed Atlantic salmon.
    Flengsrud R
    Glycoconj J; 2016 Apr; 33(2):121-3. PubMed ID: 26993287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular weight molluscan glycosaminoglycan from bivalve Katelysia opima (Gmelin).
    Vijayabaskar P; Balasubramanian T; Somasundaram ST
    Methods Find Exp Clin Pharmacol; 2008 Apr; 30(3):175-80. PubMed ID: 18597000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effects.
    Saivin S; Petitou M; Lormeau JC; Dupouy D; Sie P; Caranobe C; Houin G; Boneu B
    J Lab Clin Med; 1992 Feb; 119(2):189-96. PubMed ID: 1740633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.